Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT
Description:
This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.
Sponsor:
Jonsson Comprehensive Cancer Center (UCLA)
Contacts:
Soosan Roodbarisroodbari@mednet.ucla.edu
310 794-1596
Government Study Link:
NCT02902757 - Click here to see study onClinicalTrials.gov
- Intention to start therapy
- Patients with histologically proven high grade glioma
- Inability to give written consent
- Severe psychiatric illness
- Breast feeding / pregnancy
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
Not yet provided. Contact Soosan Roodbari for more information.
310 794-1596
sroodbari@mednet.ucla.edu
